Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

CHICA­GO — Boehringer In­gel­heim’s tar­get­ed lung can­cer drug led to durable re­spons­es, ac­cord­ing to the lat­est da­ta from the ear­ly-stage tri­al.

The Ger­man drug­mak­er is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER